CLINICAL_TRIALS
trial_result
· 2024-10-08
Clinical Trial Update: Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy [Phase 3]
Summary
A Phase 3 trial evaluating ligelizumab (QGE031) for peanut allergy was terminated, with efficacy and safety results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis Pharmaceuticals | Conditions: Allergy, Peanut | Phase 3 | Status: TERMINATED | Results posted: 2024-10-08